Science is at a hinge moment, with the convergence of biotechnology and technology driving rapid advances in the research and discovery of new ways to help people living with cancer. Human data now enables clinical trials that are more precise in targeting biomarker-selected populations, as well as more accessible to diverse patient populations.
Translational research is another crucial step in the process of bringing new and transformative medicines to patients with the greatest unmet need, and it is not possible without collaboration. The newly launched Amgen Partners of Choice network was created to foster collaboration and address the shared goal of improving the lives of patients living with cancer. Amgen Partners of Choice brings Amgen's deep and diversified oncology pipeline together with world-class clinical leaders to accelerate the discovery of new therapies for patients facing complex, difficult-to-treat cancers. The network aims to create multiple collaboration channels with the goal of advancing drug development and discovery to help improve the lives of patients.
Amgen Partners of Choice Scientific Summit
In June, Amgen hosted the inaugural scientific summit at its headquarters, convening APoC network partners, including 35 clinical leaders from eight institutions across the world:
- Asan Medical Center (Seoul, South Korea)
- Dana-Farber Cancer Institute (Boston)
- West German Cancer Center at University Hospital Essen (Essen, Germany)
- Gustave Roussy (Paris)
- Memorial Sloan Kettering Cancer Center (New York)
- Peter MacCallum Cancer Centre (Melbourne, Australia)
- University Health Network's Princess Margaret Cancer Centre (Toronto)
- Vall d'Hebron Institute of Oncology (Barcelona, Spain)
Attendees discussed the future of the Amgen Partners of Choice network and how it intends to help improve the lives of patients living with cancer by bringing transformational programs to the clinic faster through translational research.
During the summit, attendees also heard from experts about emerging oncology advances, including Dave Reese, MD, executive vice president, Research and Development, Amgen, who discussed the importance of translational research in drug discovery. Ray Deshaies, senior vice president, Global Research, Amgen, spoke about the future of molecular medicine, while Alan Russell, vice president, Research Biologics, Amgen, analyzed the evolution of drug discovery and the new era of generative science thanks to advances in machine learning. Attendees also had a chance to hear from select Amgen Partners of Choice members as part of a panel discussion about antibody-drug conjugates in the field of oncology.
The next network-wide scientific summit will take place virtually later this year.
For more information on Amgen's robust portfolio and pipeline, visit AmgenOncology.com.